Effects of C358A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase on weight loss and cardiovascular risk factors 1 year after biliopancreatic diversion surgery

Background: Bariatric surgery is the most effective long-term treatment of morbid obesity and also results in a reduction of obesity-associated co-morbidities We investigated the role of the polymorphism (C358A) of the fatty acid amide hydrolase gene on the clinical outcomes 1 year after biliopancreatic diversion in morbidly obese patients Methods: A total of 67 morbidly obese patients (body mass index >40 kg/m(2)) underwent biliopancreatic diversion Their weight. blood pressure. basal glucose. triglycerides, total cholesterol, low-density lipoprotein cholesterol. and high-density lipoprotein cholesterol were measured at the baseline visit and at each follow-up visit The frequency of the metabolic co-morbidities was recorded at each visit Results: Of the 67 patients. 46 (68 7%) had genotype C358C (wild-type group) and 21 (10 3%) had genotype 058,4 (mutant-type group) In the wild- and mutant-type groups, the body mass index, weight, waist circumference. systolic blood pressure. and glucose, total cholesterol, low-density lipoprotein cholesterol, and triglyceride concentrations decreased. without statistical significance between the 2 groups The initial percentage of weight loss at 9 months and 1 year of follow-up was greater in the mutant-type group (9 months, 22 1% versus 28 8%. P < 05. and 1 year. 28 3% versus 36 4%. P < 05) Conclusion: The allele A358 of fatty acid amide hydrolase was associated with a better initial percentage of excess weight loss 9 and 12 months after biliwopancreatic diversion (Surg Obes Relat 2010.6 516-520) (c) 2010 American Society for Metabolic and Bariatric Surgery All rights reserved